HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained the price target of $87.
December 22, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on Legend Biotech with an unchanged price target of $87, potentially influencing investor confidence and stock performance.
The reiteration of a Buy rating by a prominent analyst can positively influence investor sentiment and potentially lead to an increase in the stock's price in the short term, especially when the price target suggests a significant upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100